Anthropic杀入AI制药的100天，药王礼来都开始慌了！

TL;DR - Anthropic is expanding into AI-driven drug discovery through acquisitions, life-sciences hiring, Claude Science, and support for rare-disease research. Its move toward autonomously advancing preclinical pipelines could make it both a technology partner and a competitor to pharmaceutical companies.

• Claude Science uses a multi-agent architecture that creates and assigns subagents to scientific research tasks.
• Anthropic plans to target commercially neglected rare diseases and offered selected projects up to $50,000 in Claude credits.
• The company acquired Coefficient Bio and hired AlphaFold co-creator John Jumper while building a biology-focused team and laboratory operations.
• Restrictions on Anthropic’s frontier models for biology and chemistry have prompted concerns about dependence on proprietary AI platforms.